RG RGNX REGENXBIO Inc. Loading... : Bullish and Bearish Analyst Opinions

Premarket movers show hyperscalers declining while chip stocks rise, with notable gains in Apogee Therapeutics on an AbbVie acquisition and Getty Images soaring on an OpenAI partnership.

US pre-market movers include Getty Images up 105% on an OpenAI display deal, Apple down 1% on device price pressures, and Apogee up 50% on an AbbVie acquisition agreement.

The head of the FDA's division of vaccines and gene therapies set to leave the agency next month... to the expectation maybe a better and some more supportive landscape from the FDA for these kinds of companies. Regulatory bottlenecks are the primary headwind for clinical-stage biotechs. A change in FDA leadership that brings a more lenient or supportive stance will accelerate trial approvals and shorten the timeline to commercialization for biological and gene therapies. LONG. Anticipated deregulation acts as a sector-wide tailwind, disproportionately benefiting small-cap clinical-stage biotechs that rely on smooth FDA pathways. Clinical trials could still fail on efficacy or safety grounds regardless of who is leading the FDA division.